Aurinia Pharmaceuticals Inc. (AUPH)

Stock Price Forecast

The 2 analysts that cover Aurinia Pharmaceuticals stock have a consensus rating of "Strong Buy" and an average price target of $11.5, which forecasts a 43.21% increase in the stock price over the next year. The lowest target is $10 and the highest is $13.

Price Target: $11.5 (+43.21%)

Analyst Consensus: Strong Buy

Target	Low	Average	Median	High
Price	$10	$11.5	$13	$13
Change	+24.53%	+43.21%	+61.89%	+61.89%

* Price targets were last updated on Sep 16, 2024.

Analyst Ratings

The average analyst rating for Aurinia Pharmaceuticals stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Rating	Jan '25	Feb '25	Mar '25	Apr '25	May '25	Jun '25
Strong Buy	1	1	1	1	1	1
Buy	2	2	2	2	2	1
Hold	0	0	0	0	0	0
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	3	3	3	3	3	2

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Olivia Brayer Cantor Fitzgerald	Cantor Fitzgerald	Buy Reiterates $10	Buy	Reiterates	$10	+24.53%	Sep 16, 2024
Olivia Brayer Cantor Fitzgerald	Cantor Fitzgerald	Buy Reiterates $10	Buy	Reiterates	$10	+24.53%	Sep 9, 2024
Ed Arce HC Wainwright & Co.	HC Wainwright & Co.	Strong Buy Reiterates $13	Strong Buy	Reiterates	$13	+61.89%	Sep 6, 2024
Ed Arce HC Wainwright & Co.	HC Wainwright & Co.	Strong Buy Reiterates $13	Strong Buy	Reiterates	$13	+61.89%	Mar 1, 2024
Olivia Brayer Cantor Fitzgerald	Cantor Fitzgerald	Buy Maintains $12 → $10	Buy	Maintains	$12 → $10	+24.53%	Feb 23, 2024

More Analyst Ratings

Financial Forecast

Revenue This Year

263.69M

Increased by 12.15%

from 235.13M

Revenue Next Year

311.96M

Increased by 18.31%

from 263.69M

EPS This Year

0.60

Increased by 1,394.30%

from 0.04

EPS Next Year

0.77

Increased by 29.35%

from 0.60

Fiscal Year	FY 2020	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026	FY 2027
Period Ending	Dec 31, 2020	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026	Dec 31, 2027
Revenue	50.12M	45.61M	134.03M	175.51M	235.13M	263.69M	311.96M	364.60M
Revenue Growth	15,660.38%	-9.01%	193.89%	30.95%	33.97%	12.15%	18.31%	16.87%
EPS	-0.87	-1.40	-0.76	-0.54	0.04	0.60	0.77	1.05
EPS Growth	-	-	-	-	-	1,394.30%	29.35%	35.55%
Forward PE	-	-	-	-	-	13.43	10.39	7.66
No. Analysts	-	-	-	-	-	7	7	6

Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue	2025	2026	2027	2028	2029
High	273.0M	373.6M	469.0M
Avg	263.7M	312.0M	364.6M
Low	251.1M	284.2M	313.6M

Revenue Growth

Revenue Growth	2025	2026	2027	2028	2029
High	16.1%	41.7%	50.3%
Avg	12.1%	18.3%	16.9%
Low	6.8%	7.8%	0.5%

EPS Forecast

EPS	2025	2026	2027	2028	2029
High	0.80	1.25	1.63
Avg	0.60	0.77	1.05
Low	0.44	0.53	0.78

EPS Growth

EPS Growth	2025	2026	2027	2028	2029
High	1,895.0%	109.0%	110.5%
Avg	1,394.3%	29.4%	35.6%
Low	1,002.5%	-11.5%	1.4%

Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.